Global leader in noninvasive monitoring and pioneer of fingertip pulse oximetry marks milestone anniversary, celebrating a 40-year legacy of accuracy and partnership while advancing further into integrated, connected health solutions under the leadership of new CEO Todd Austin.
Nonin Medical, a leading global manufacturer of wearable and noninvasive patient monitoring solutions, is celebrating its 40th anniversary in 2026, marking four decades of innovation in patient monitoring and solidifying its role as a trusted partner to clinicians, sleep specialists, home care providers, respiratory therapists, and OEM customers worldwide. This milestone honors the company’s foundational role in shaping modern noninvasive patient monitoring while reinforcing its long-term commitment to accuracy, quality, and customer partnership. As part of this milestone year, the appointment of Todd Austin as CEO positions a seasoned clinician-executive to guide the next chapter of growth.
Founded in 1986 by engineer and entrepreneur Phil Isaacson, Nonin was built on the principle that accurate measurements matter. When clinicians can trust the data in front of them, they make better decisions, and better decisions lead to better patient outcomes. That philosophy, earning trust through consistency, evidence, and engineering discipline, became the foundation of Nonin’s culture and remains embedded in every solution the company develops.
“From the very beginning, our goal was to give clinicians data they could depend on without question. “Trust is earned through consistency, evidence, and performance. For four decades, every product we have ever built starts and ends with those standards,” says Phil Isaacson, founder and Executive Chairman of the Board, Nonin Medical. Isaacson will continue to serve as Executive Chairman and Chief Technology Officer as the company enters its fifth decade, maintaining continuity of vision and technical leadership.
In 1995, the company introduced the world’s first fingertip pulse oximeter. At the time, pulse oximetry was largely confined to larger hospital-based systems. Nonin’s innovation miniaturized the technology without compromising accuracy or durability, fundamentally redefining accessibility in patient monitoring. The fingertip oximeter established new benchmarks for reliability and clinical trust, benchmarks that continue to guide the company’s product development today. Four decades on, Nonin’s technology is embedded in hospitals, home health settings, sleep laboratories, research institutions, and OEM platforms in more than 125 countries.
For forty years, Nonin has been a trusted partner across the full spectrum of noninvasive monitoring, from critical respiratory care to sleep medicine. In respiratory care, accurate measurements are essential for assessing and managing chronic conditions, including COPD and asthma, in patient populations growing rapidly worldwide. In sleep medicine, Nonin’s technology provides the reliable data that clinicians depend on when diagnosing and managing obstructive sleep apnea, one of the most prevalent and underdiagnosed conditions globally. Across both disciplines, and in home-based and connected care settings, Nonin’s solutions have served as a consistent, clinically trusted partner for patients and providers alike.
As healthcare delivery increasingly extends beyond traditional hospital walls into homes, decentralized research models, and digitally connected ecosystems, the need for accurate, reliable noninvasive data has only intensified. To guide the company into this next chapter of more connected care provision, Nonin has appointed Todd Austin as Chief Executive Officer. Austin’s appointment reflects a deliberate choice to lead Nonin’s evolution with a clinician who has spent more than four decades understanding respiratory care from both the bedside and the boardroom.
A registered respiratory therapist, registered pulmonary function technologist, and neonatal-pediatric specialist, Austin began his career at the bedside in the early 1980s, caring for critically ill patients in neonatal and pediatric intensive care. Austin witnessed the emergence of pulse oximetry as the “fifth vital sign,” a transformation that fundamentally changed how clinicians assess and manage respiratory conditions. Over a career spanning SensorMedics, VIASYS Healthcare, CareFusion, and, most recently, as President and CEO of MGC Diagnostics, Austin has translated clinical insight into commercial leadership across pulmonary diagnostics, sleep medicine, and global medical technology.
“Nonin was a familiar part of my clinical work long before I ever imagined leading the company. As a clinician, you learn very quickly that accuracy is not a feature; it’s a responsibility. Forty years of trust is something you protect fiercely, even as you push forward with the next wave of innovation,” says Todd Austin, CEO, Nonin Medical.
“Todd brings a rare combination of clinical credibility, operational leadership, and deep respect for the culture that has sustained Nonin for forty years. This is not a moment of reinvention; it’s a moment of sustained evolution and continued innovation. Todd understands what must remain unchanged, and where we have an opportunity to lead for decades to come,” Isaacson explains.
Austin’s vision for Nonin’s next chapter centers on expanding what the company’s legacy of accuracy can deliver as healthcare evolves rapidly toward connected, home-based, and personalized care models. That means building on the company’s trusted hardware foundation with integrated software solutions, including Nonin Health, the company’s cloud-based data platform, designed to transform accurate, dependable SpO₂ data into actionable clinical and physiological insights accessible across care settings. It also means ensuring that the accuracy and equity Nonin has always stood for reach patients wherever care takes place, including in remote and underserved communities.
“Our legacy of accuracy is strong. Our future of innovation is even stronger. What excites me most is the shift toward proactive, connected care that can reach patients wherever they are, and the recognition that its success depends on one fundamental principle: the data must be accurate, reliable, and accessible. For 40 years, that has been Nonin’s standard. As care becomes more connected and more personal, that foundation becomes even more critical,” Austin continues.
As Nonin enters its fifth decade, the company will celebrate its 40th anniversary throughout 2026 with initiatives honoring its history, its customers and partners, and the future of noninvasive monitoring. Advances in miniaturization, connectivity, and analytics are enabling more personalized monitoring strategies, moving beyond comparisons to population norms toward a clearer understanding of individual patient baselines. In respiratory and sleep care alike, ensuring that these emerging models are built on dependable data and insights remains central to Nonin’s direction.